99mTc-H7ND SPECT/CT Imaging in NSCLC

This study was a prospective, controlled, single-center clinical study.

To evaluate the value of 99mTc-H7ND imaging in the evaluation of stable disease in patients with non-small cell lung cancer (NSCLC) assessed by RECIST1.1, and to predict the efficacy of subsequent treatment (second-line treatment).

Patients with NSCLC confirmed by cytology or pathology, who were unable to undergo radical surgery because of recurrence, metastasis, or their own conditions, and who had completed 2-4 cycles of first-line therapy and had RECIST1.1 assessment (SD) were divided into 2 groups:

Experimental group: 99mTc-H7ND SPECT/CT imaging performed Control group: 99mTc-H7ND SPECT/CT imaging was not performed

Inclusion criteria

• Patients aged from 18 to 80 years old;
• patients with NSCLC confirmed by needle aspiration cytology or surgical pathology, who cannot undergo radical surgery due to recurrence, metastasis or patient's own conditions;
• Has completed 2-4 cycles of first-line therapy (including chemotherapy, immunotherapy, chemotherapy combined with immunotherapy, chemotherapy combined with targeted therapy, etc.), and has SD assessed by RECIST 1.1 during the same period;
• Patients had at least one measurable lesion;
• No local radiotherapy for primary or metastatic lesions within 28 days;
• ECOG score 0-2;
• Expected survival time ≥3 months;
• Voluntarily participate and sign informed consent.

Exclusion criteria

• Women who plan to become pregnant within 6 months, or are pregnant or lactating.
• Patients with severe brain or bone metastases;
• Severe anemia and severe liver and kidney damage;
• Pathological or long-term follow-up results may not be available;
• The relevant control imaging data and clinical data were not available;
• Severe illness is difficult to cooperate (such as acute cardiovascular and cerebrovascular events or serious cardiovascular diseases);
• Received any surgery or invasive treatment or procedure within 4 weeks before enrollment;
• Cannot tolerate standard second-line therapy or other first-line therapies.
• Known allergy to 99mTc-H7ND or any of its components; He had a history of severe allergies;
• Protocol imaging contraindications were present;
• The investigator considered it inappropriate to participate in the study.